Literature DB >> 28300886

Disseminated cryptococcosis manifested as a single tumor in an immunocompetent patient, similar to the cutaneous primary forms.

Danielle Mechereffe do Amaral1, Ritha de Cássia Capelato Rocha1, Luiz Euribel Prestes Carneiro1, Dewton Moraes Vasconcelos2, Marilda Aparecida Milanez Morgado de Abreu1.   

Abstract

Cryptococcosis is a fungal infection caused by Cryptococcus neoformans that tends to affect immunocompromised individuals. The fungi are mostly acquired by inhalation, which leads to an initial pulmonary infection. Later, other organs - such as the central nervous system and the skin - can be affected by hematogenous spread. In addition, cutaneous contamination can occur by primary inoculation after injuries (primary cutaneous cryptococcosis), whose diagnosis is defined based on the absence of systemic involvement. The clinical presentation of cutaneous forms typically vary according to the infection mode. We report an unusual case of disseminated cryptococcosis in an immunocompetent patient with cutaneous lesions similar to those caused by primary inoculation. This clinical picture leads us to question the definition of primary cutaneous cryptococcosis established in the literature.

Entities:  

Mesh:

Year:  2016        PMID: 28300886      PMCID: PMC5324985          DOI: 10.1590/abd1806-4841.20164582

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


INTRODUCTION

Cryptococcosis is a fungal infection caused by two varieties of Cryptococcus neoformans, which are divided into five serotypes: serotypes A, D, and AD (C. neoformans var. neoformans) and serotypes B and C (C. neoformans var. gatti).[1] Serotype A has a worldwide distribution and is found in most of Brazil; serotype D is found mainly in the Europe; and C. neoformans var. gattii is limited to tropical and subtropical areas.[2] This fungus has a wide environmental distribution and is found in tree branches, bird feces, soil, fruit, and vegetables.[3] Low global frequency of cryptococcosis indicates that the host immune response is sufficient to prevent demonstrations in most immunocompetent patients. However, the disease has been increasingly found in immunocompromised patients, especially HIV-infected individuals.[1,2] The disease is spread mostly through inhalation of fungi, which usually cause asymptomatic pulmonary infection. However, the disease can spread through the blood, affecting preferably the central nervous system (CNS) and skin, called disseminated cryptococcosis (DC). Another portal of entry is the inoculation of the fungus via skin injury (primary cutaneous cryptococcosis - PCC).[4] To be considered a primary cutaneous disorder, the disease must have the following features: be exclusively cutaneous, have positive culture for fungus, and show absence of systemic involvement.[5] Cryptococcosis diagnosis is made by histopathology of the infected tissue, direct detection of fungus in body fluids with India ink examination, isolation in tissue culture, and detection of cryptococcal polysaccharide antigen in the serum and in the cerebrospinal fluid through agglutination by latex or ELISA. The latter test has a prognostic significance (high titers can be predictors of disseminated disease) and serves for therapeutic monitoring.[6] If infection is present in one area, without CNS involvement or immunosuppression, the treatment is conducted with oral fluconazole, 400 mg/daily for 6-12 months. For cryptococcal meningitis, recommended treatment consists of a two-week induction therapy with intravenous amphotericin B, 0.7-1 mg/kg/day, followed by a consolidation phase with oral fluconazole 800mg/day for eight weeks. Thereafter, maintenance therapy with fluconazole 400 mg/day is suggested for 6-12 months, or until immune restoration.[7] We report an unusual case of DC in an immunocompetent patient with skin lesions similar to those caused by primary cutaneous inoculation, which leads us to question the accepted definition of PCC and DC as distinct entities.

CASE REPORT

We report a 68-year-old white male patient born and raised in Tupi (SP), rural worker, who complained about a 30-day asymptomatic lesion on his right forearm, with progressive growth and subsequent ulceration. He reported that he had handled a mortar bag two days before the lesion occurred. The patient presented with poorly defined erythematous plaque (about 25cm in size) on the right forearm, displaying multiple nodules on the surface, some with fluctuation and discharging gelatinous secretion after puncture, and some ulcerated areas covered by crusts (Figures 1-3).
Figure 1

Erythematous plaque with multiple soft and friable nodules

Figure 3

Gelatinous secretion

Erythematous plaque with multiple soft and friable nodules Details of the nodules Gelatinous secretion He also reported holocranial tension headache, of low intensity, three days before, associated with nausea and asthenia. He denied fever. The patient revealed a personal history of chronic obstructive pulmonary disease for 10 years, with chronic use of corticosteroid inhalers. He was a smoker (100 packs/year) and ex-alcoholic.

General physical examination was normal.

Histopathological examination of the skin biopsy showed granulomas in the dermis with presence of intermingled fungi morphologically compatible with Cryptococcus spp (Figure 4). Mucicarmine and Grocott-Gomori staining showed numerous yeasts in budding (Figure 5).
Figure 4

Histopathological examination (HE): encapsulated yeast in the dermis

Figure 5

Grocott-Gomori-stained budding yeasts

Histopathological examination (HE): encapsulated yeast in the dermis Grocott-Gomori-stained budding yeasts Culture for fungi revealed brownish yeast colony with creamy and viscous appearance, whose microcultivation showed encapsulated budding blastoconidia, features of Cryptococcus neoformans. Cultures for bacteria and mycobacteria were negative. In systemic investigation, computed tomography was consistent with pulmonary emphysema, with no other relevant findings; CT scans of the abdomen and skull were normal. Fungal blood and urine cultures were negative. Examination of the cerebrospinal fluid showed lymphocytic meningitis attributed to cryptococcosis. Cryptococcal antigen survey in CSF was positive (1:1024). Based on the findings, we diagnosed DC with proven skin and neurological involvement. Serology for HIV, serum immunoglobulins (IgG, IgM, and IgA), protein electrophoresis, blood count, biochemical tests, and immunophenotyping of peripheral blood (CD4, CD8, CD19, CD56, CD45RO/CD4) were normal. Our patient was treated with intravenous liposomal amphotericin B, 5mg/kg/day for two weeks, followed by fluconazole, with a 12-month treatment. Response to treatment was favorable showing an almost complete remission of cutaneous lesions in six months. The patient is being followed up.

DISCUSSION

Skin involvement in DC patients occurs in approximately 10% of cases, which may be the primary manifestation of the disease and an early sign of dissemination.[2,4,8] However, PCC is rare and still controversial. PCC occurs in a population with different personal features (age, gender), immune status, geographic locations compared to DC, suggesting that the diseases are clinically distinct entities. PCC has a predilection for immunocompetent or immunocompromised elderly male patients residents of rural areas.[9] Cellulitis and ulceration in a limited and exposed cutaneous area, especially on the upper limbs, are the most common manifestations. Gelatinous exudation is common. Most cases present a local trauma history and exposure to bird feces.[3] DC cutaneous lesions usually spread affecting unexposed and exposed areas. Lesions can appear in any type: umbilicated (mimicking molluscum contagiosum), acneiform, nodular, herpetiform, and cellulitis-like lesions.[4,9] However, lesions mimicking PCC, as reported in our case, are an exceptional feature. Systemic cryptococcal infection in immunocompetent patients, as in our case, is rare. Some cases of opportunistic infections have been reported in chronic users of high doses of inhaled corticosteroids, particularly pulmonary aspergillosis, but no DC report was found in the literature.[10] Despite the prolonged use of inhaled corticosteroids by our patient, we observed no immunosuppression in the immunologic research. Based on our report, we question, therefore, the validity of the current concept of PCC and DC as different entities. Our patient lived in the rural area, was apparently immunocompetent, and presented with a lesion on an exposed area, features suggestive of PCC. However, the presence of meningitis defined the diagnosis of DC. The results point to the need for comprehensive systemic investigation in all cases of cryptococcosis, even in immunocompetent patients with localized cutaneous lesions. Non-diagnosis of occult systemic alterations can result in catastrophic consequences to the patient due to inappropriate treatment.
  10 in total

1.  Primary cutaneous cryptococcosis in immunocompetent hosts.

Authors:  A Spiliopoulou; E D Anastassiou; M Christofidou
Journal:  Mycoses       Date:  2012-03       Impact factor: 4.377

Review 2.  Primay cutaneous cryptococcosis in an immunocompetent patient.

Authors:  Nilton Nasser; Nilton Nasser Filho; Andreza Guimarães Vieira
Journal:  An Bras Dermatol       Date:  2011 Nov-Dec       Impact factor: 1.896

Review 3.  Cryptococcosis diagnosis and treatment: What do we know now.

Authors:  John R Perfect; Tihana Bicanic
Journal:  Fungal Genet Biol       Date:  2014-10-13       Impact factor: 3.495

4.  Primary cutaneous cryptococcosis in Brazil: report of 11 cases in immunocompetent and immunosuppressed patients.

Authors:  Sílvio A Marques; Ivander Bastazini; Ana L G P Martins; Jaison A Barreto; Maria P Barbieri D'Elia; Joel C Lastória; Mariangela E A Marques
Journal:  Int J Dermatol       Date:  2012-07       Impact factor: 2.736

5.  Cryptococcal meningitis with secondary cutaneous involvement in an immunocompetent host.

Authors:  Saadia Tabassum; Atiya Rahman; Fivzia Herekar; Sadia Masood
Journal:  J Infect Dev Ctries       Date:  2013-09-16       Impact factor: 0.968

6.  Primary cutaneous cryptococcosis: a distinct clinical entity.

Authors:  Ségolène Neuville; Françoise Dromer; Odile Morin; Bertrand Dupont; Olivier Ronin; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2003-01-17       Impact factor: 9.079

7.  Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy.

Authors:  Elvis Peter; Faris Bakri; Donna M Ball; Richard T Cheney; Brahm H Segal
Journal:  Clin Infect Dis       Date:  2002-07-31       Impact factor: 9.079

8.  Primary cutaneous cryptococcosis in an immunocompetent host.

Authors:  Monica Pau; Cesarina Lallai; Natalia Aste; Nicola Aste; Laura Atzori
Journal:  Mycoses       Date:  2009-03-14       Impact factor: 4.377

9.  Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host.

Authors:  Carlos Alberto Leão; Kennio Ferreira-Paim; Leonardo Andrade-Silva; Delio Jose Mora; Paulo Roberto da Silva; Anna Silva Machado; Priscila Freitas Das Neves; Giovana Silva Pena; Luciana Silva de Almeida Teixeira; Mario León Silva-Vergara
Journal:  Med Mycol       Date:  2010-10-28       Impact factor: 4.076

10.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

  10 in total
  6 in total

Review 1.  Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.

Authors:  Fabíolla Nacimento do Carmo; Juliana de Camargo Fenley; Maíra Terra Garcia; Rodnei Dennis Rossoni; Juliana Campos Junqueira; Patrícia Pimentel de Barros; Liliana Scorzoni
Journal:  Braz J Microbiol       Date:  2022-04-29       Impact factor: 2.214

2.  Fulminant cryptococcal meningoencephalitis after successful treatment of primary cutaneous cryptococcosis.

Authors:  Iordanis Romiopoulos; Zoi Dorothea Pana; Athina Pyrpasopoulou; Ioanna Linardou; Eugenia Avdelidi; Maria Sidiropoulou; Eleni Chatzidrosou; Dimitrios Ioannides; Asterios Karagiannis; Emmanuel Roilides
Journal:  Germs       Date:  2020-12-28

3.  Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection.

Authors:  Isabel Ferreira LaRocque-de-Freitas; Juliana Dutra B Rocha; Marise Pinheiro Nunes; Priscila Angelica V Oliveira; Danielle de Oliveira Nascimento; Leonardo Freire-de-Lima; Christina Maeda Takiya; Alexandre Morrot; Debora Decote-Ricardo; Jose Osvaldo Previato; George A DosReis; Lucia Mendonça-Previato; Celio Geraldo Freire-de-Lima
Journal:  Sci Rep       Date:  2018-11-06       Impact factor: 4.379

4.  Disseminated cryptococcal infection in an immunocompetent patient treated with short course induction therapy.

Authors:  Alice Parry; Richard Doxey; Rachel Herbert; Ian Moonsie; Neil Stone
Journal:  Med Mycol Case Rep       Date:  2020-12-24

5.  Early clinical and microbiological predictors of outcome in hospitalized patients with cryptococcal meningitis.

Authors:  Lidiane de Oliveira; Marcia de Souza Carvalho Melhem; Renata Buccheri; Oscar José Chagas; José Ernesto Vidal; Fredi Alexander Diaz-Quijano
Journal:  BMC Infect Dis       Date:  2022-02-09       Impact factor: 3.090

6.  Primary Cutaneous Cryptococcosis Caused by Cryptococcus gatti in an Elderly Patient.

Authors:  Walter Belda; Ana T S Casolato; Juliana B Luppi; Luiz Felipe D Passero; Paulo R Criado
Journal:  Trop Med Infect Dis       Date:  2022-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.